Allogene Therapeutics Inc (ALLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has a cash flow conversion efficiency ratio of -0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.69 Million) by net assets ($315.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Allogene Therapeutics Inc for the company's overall valuation and market capitalisation.
Allogene Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allogene Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allogene Therapeutics Inc ranked by their cash flow conversion efficiency. See Allogene Therapeutics Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ranger Energy Services Inc
NYSE:RNGR
|
0.050x |
|
Jiangsu Rutong Petro-Machinery
SHG:603036
|
0.042x |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
0.122x |
|
Proact IT Group AB
ST:PACT
|
0.098x |
|
Schweiter Technologies AG
SW:SWTQ
|
0.037x |
|
Nanjing Inform Storage Equip
SHG:603066
|
-0.012x |
|
Bank of Marin Bancorp
NASDAQ:BMRC
|
0.032x |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
0.028x |
Annual Cash Flow Conversion Efficiency for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Allogene Therapeutics Inc from 2017 to 2024. View latest Allogene Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $422.18 Million | $-200.30 Million | -0.474x | -2.23% |
| 2023-12-31 | $512.23 Million | $-237.73 Million | -0.464x | -40.35% |
| 2022-12-31 | $666.88 Million | $-220.52 Million | -0.331x | -65.54% |
| 2021-12-31 | $925.20 Million | $-184.81 Million | -0.200x | -87.38% |
| 2020-12-31 | $1.08 Billion | $-115.09 Million | -0.107x | +51.18% |
| 2019-12-31 | $629.02 Million | $-137.35 Million | -0.218x | -243.85% |
| 2018-12-31 | $703.16 Million | $-44.65 Million | -0.064x | -100.00% |
| 2017-12-31 | $-2.00K | $-44.65 Million | 22326.500x | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more